/

Society

GL

Society

GLOBENEWSWIRE

What we write about

15517 Press releases

View all press releases

18/04/2026

Want ads

LIMITLESS WORKSPACE – Where Design Performs

Source

Issuer

1.00

0

18/04/2026

Biotechnology

Medical Health Wellness

Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026

Source

Theriva Biologics, Inc.

Issuer

1.00

0

18/04/2026

iCAUR V27 Secures CATARC L3 Off-Road Certification, Solidifying Its New Energy Off-Road Capability with Robust Technology

Source

Issuer

1.00

0

18/04/2026

Pharmaceuticals

Foreign Policy

Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe

Source

Sanofi Winthrop Industrie

Issuer

1.00

0

18/04/2026

Pharmaceuticals

Foreign Policy

Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Source

Sanofi Winthrop Industrie

Issuer

1.00

0

17/04/2026

Media

Fotografia

2026 Fujian Provincial Conference on Development of Cultural, Tourism Economy opens on Apr. 17 in Zhangzhou, SE China's Fujian

Source

Organizing Committee of the 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy

Issuer

1.00

0

Press Release cover image

17/04/2026

Media

L'Alliance BRIDGE prolonge la durée de son sommet à cinq jours à mesure qu’elle développe sa plateforme médiatique mondiale

Source

L'Alliance BRIDGE

Issuer

1.00

0

17/04/2026

Biotechnology

Medical Health Wellness

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Source

Theriva Biologics, Inc.

Issuer

1.00

0

17/04/2026

Biotechnology

Want ads

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Source

Issuer

1.00

0

17/04/2026

Biotechnology

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Source

Issuer

1.00

0

Followers

0

Compatibility

0